Navigation Links
Independent publication supports the profile of CeNeS phase II,compound, CNS 5161

CAMBRIDGE, England, 4th May 2007 - CeNeS Pharmaceuticals plc (LSE: CEN), the Cambridge based biopharmaceutical company, notes the publication of an independent study in the respected scientific journal 'Synapse'* on its Phase II NMDA antagonist, CNS 5161. CeNeS is developing CNS 5161 as a potential treatment for neuropathic pain. The independent study builds on the work that CeNeS has already undertaken with CNS 5161.

In the study reported in 'Synapse', Dr Anat Biegon and her group at the Brookhaven National Laboratory, New York, USA, have studied a radioactively labelled version of CNS 5161. They have shown that CNS 5161 is a selective and high affinity NMDA receptor antagonist with preferential binding to the activated form of the receptor. The group also demonstrated that CNS 5161 penetrates the brain well and can be used to label selectively brain NMDA receptors in vivo. Dr Biegon proposes that a radioactive form of CNS 5161 may be used as an agent to monitor NMDA receptors in the human brain using Positron Emission Tomography ("PET") and notes that "the significance of a selective, validated radiopharmaceutical agent suitable for detecting widespread as well as highly localized changes in the NMDA receptor in the living brain cannot be exaggerated".

Data from Phase I and Phase IIa studies previously carried out by CeNeS have shown that CNS 5161 has analgesic properties in patients with neuropathic pain, but does not induce the severe psychotomimetic side-effects associated with other NMDA antagonists.

Neil Clark, Chief Executive of CeNeS, said:

"The data published in this paper supports and extends our original findings with CNS 5161. It has proved very difficult to develop a PET agent with the properties that make it possible to monitor NMDA receptor activation in the human brain. The profile of CNS 5161 as a selective, high affinity and brain-penetrating agent now make this a possibility. These properties of CNS 5161, together with its low liability to induce side-effects, are the scientific foundation for our clinical development programme of CNS 5161 as a novel treatment for the major neuropathic pain market. We plan to test CNS 5161 in further Phase II trials in cancer pain and neuropathic pain later this year."

*In vitro and in vivo characterization of [3H]CNS-5161. A use-dependent ligand for the N-methyl-d-aspartate receptor in rat brain. Biegon et al., Synapse, volume 61, pages 577-586, 2007.

For more information please contact: CeNeS Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)1223 266 466

JM Finn Geoff Nash Tel: +44(0) 207 628 9688

Financial Dynamics Ben Brewerton/Emma Thompson Tel: + 44 (0) 207 831 3113

About CeNeS Pharmaceuticals CeNeS is a biopharmaceutical company specialising in the development and commercialisation of drugs for pain control, sedation and other CNS disorders such as Parkinson's disease. The company is based in Cambridge, England. For further information visit the CeNeS web site: www.cenes.com

About CNS 5161 A range of primary diseases or conditions such as diabetes, cancer, HIV/Aids and shingles, or surgical procedures such as limb amputation can result in nerve damage which leads to a sustained chronic pain. This neuropathic pain is difficult to treat as traditional analgesics do not provide adequate relief for many patients. Drug treatments for neuropathic pain represent a significant area of unmet medical need and a growing market opportunity that is currently valued at over $2 billion globally. Glutamate (particularly NMDA) receptors have been implicated in the induction and maintenance of neuropathic pain and NMDA antagonists may represent a class of drugs for effective relief of neuropathic pain. CNS 5161 is a blocker of the NMDA ion channel and has completed Phase I and more recently Phase IIa proof of c oncept clinical trials as a novel compound for the treatment of neuropathic pain. Two Phase I studies using CNS 5161 administered intravenously have been completed in male volunteers. The first study demonstrated the safety and tolerability of selected doses of CNS 5161 and the second that at a dose of CNS 5161 that was well tolerated, analgesic effects were evident in an experimental model of pain. Two phase IIa studies have been completed giving single dose intravenous infusions of CNS 5161 to patients with long standing intractable neuropathic pain. A total of 48 patients have received CNS 5161; 10 patients in an initial study and 38 patients in a study completed in 2005. Both studies reported analgesic effects of CNS 5161 at doses that were well tolerated by the patients.


'"/>




Related medicine technology :

1. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
2. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
3. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
4. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
5. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
6. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
7. CeNeS Pharmaceuticals Plc Announces Preliminary Results for The Year Ending 31 December 2006
8. CeNeS Pharmaceuticals plc: Update on Successful Phase III results announced on Lead Product M6G
9. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
10. Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy
11. Isotechnikas independent data monitoring committee conducts review of phase 2b kidney transplant trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company ... and market advanced products and therapies for the Wound ... sectors of healthcare, today announced its record results for ... 2016. Full Year 2016 Highlights are: ... full year 2015 revenue ...
(Date:2/23/2017)...   SeraCare Life Sciences , a manufacturer ... manufacturers and clinical laboratories, is announcing an upcoming ... Tests" to be hosted by GenomeWeb ... Standard Time (US). The goal of ... improved performance and global standardization in the implementation ...
(Date:2/23/2017)... , February 23, 2017 The U.S. ... legalized cannabis for recreational use in 2016. According to a ... market was worth an estimated $7.2 billion in 2016 and ... of 17%. While adult recreational sales are projected to jump ... with a 25% CAGR. The market may grow faster as ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... 23, 2017 , ... Dr. David Mahon leads Siena Dental, a comprehensive dental ... named a 2017 Top Patient Rated Henderson Dentist by Find Local Doctors ... local physicians and dentists who have earned high ratings and superior patient reviews from ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... clinical trials, today announced that Premier Research, a leading clinical development service provider, ... trials are becoming increasingly complex, due in part to an array of circumstances ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... publication and community for those in the fight against cancer, has produced a ... their success. HRA will release top-line findings in a webinar, Defining Compassionate ...
(Date:2/23/2017)... VA – , ... ... coming. It’s the perfect opportunity for the nation to come ... a college basketball bracket – with its favorite fruit – ... is encouraging apple lovers to join the “Apple Madness” bracket ...
(Date:2/23/2017)... Los Angeles, CA (PRWEB) , ... February 23, 2017 , ... ... of her Smiling Patriot program today with a new Indiegogo campaign ... dental care to homeless veterans in the Los Angeles area, either as a participating ...
Breaking Medicine News(10 mins):